NCT07557446NOT_YET_RECRUITINGanonymous

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

Sponsor

Source record

Angitia Biopharmaceuticals Guangzhou Limited

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

AGA2115

Indication / condition

AI-normalized

Osteogenesis Imperfecta (OI)

Intervention

Source record

AGA2115

Related intelligence directories

Indication directory: Osteogenesis Imperfecta (OI)Modality directory: small molecule Target directory: AGA2115

Source & freshness

Source record

NCT ID

NCT07557446

Original source

ClinicalTrials.gov

Source last updated

Apr 29, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07557446

Title

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

Sponsor

Angitia Biopharmaceuticals Guangzhou Limited

Status

NOT_YET_RECRUITING

Phase

PHASE2

Condition raw

Osteogenesis Imperfecta (OI)

Condition normalized

Osteogenesis Imperfecta (OI)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AGA2115

Target normalized

AGA2115

Interventions

AGA2115

Public preview

Source record

This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT07557446

Status

NOT_YET_RECRUITING

Phase

PHASE2

Sponsor

Angitia Biopharmaceuticals Guangzhou Limited

Executive brief

Investment-Ready Snapshot

This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 29, 2026

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07557446

Indication

Osteogenesis Imperfecta (OI)

Modality

small molecule

Target

AGA2115

Intervention

AGA2115

Source record